美国生物技术公司Monte Rosa Therapeutics(GLUE.US)于2024年10月28日盘中大涨142.13%,引发市场广泛关注。此次大涨主要源于该公司当天宣布与制药巨头诺华(NVS.US)达成分子胶降解剂MRT-6160的独家许可协议。
根据协议内容,诺华将支付1.5亿美元预付款,获得MRT-6160和其他VAV1导向分子胶降解剂在全球范围内的独家开发、生产和商业化权利。除预付款外,Monte Rosa还有机会获得高达21亿美元的开发、监管和销售里程碑付款,以及美国境外净销售额的分层版税。
作为一种新兴疗法,分子胶降解剂被视为攻克难治性疾病新手段。Monte Rosa在该领域处于领先地位,与诺华达成合作将充分利用后者在药物开发和商业化方面的资源优势,有望推进MRT-6160等产品管线价值的挖掘,长期受益可期。因此,这一利好消息一出极大提振了投资者预期,促使Monte Rosa当日股价大涨142%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.